Issue link: https://beckershealthcare.uberflip.com/i/1393415
42 POPULATION HEALTH 42 CEO / STRATEGY 15 top-paid S&P 500 CEOs in healthcare By Morgan Haefner T he CEO of Regeneron was the top-paid CEO leading an S&P 500 healthcare company in 2020, according to a rank- ing from e Wall Street Journal. For its CEO pay analysis, e Wall Street Jour- nal used information from corporate proxy statements that S&P 500 companies filed through May for fiscal years ending aer June 30, 2020. e data was collected by MyLogIQ. Pay data includes equity awards. Here are the 15 healthcare CEOs with the highest pay on e Wall Street Journal's index for 2020. 1. Leonard Schleifer, MD, PhD, CEO of Re- generon: $135.4 million 2. Javier Rodriguez, CEO of Davita: $73.4 million 3. Samuel Hazen, CEO of Nashville, Tenn.- based HCA Healthcare: $30.4 million 4. Alex Gorsky, CEO of Johnson & Johnson: $29.6 million 5. Marc Casper, CEO of ermo Fisher Scien- tific: $26.4 million 6. Ari Bousbib, CEO of Iqvia: $25.6 million 7. Michael Neidorff, CEO of Centene: $25 million 8. Richard Gonzalez, CEO of AbbVie: $24 million 9. David Ricks, CEO of Eli Lilly: $23.7 million 10. Larry Merlo, CEO of CVS Health: $23 mil- lion 11. Kenneth Frazier, CEO of Merck: $22.1 million 12. Albert Bourla, PhD, CEO of Pfizer: $21 million 13. Robert Ford, CEO of Abbott Laboratories: $20.5 million 14. Giovanni Caforio, CEO of Bristol Myers Squibb: $20.2 million 15. Robert Bradway, CEO of Amgen: $20.1 million n Initiatives that could mitigate the next health crisis, ranked by 73 experts By Kelly Gooch T he COVID-19 pandemic has sparked various discussions about what steps should be taken to prepare for the next pub- lic health crisis. To study this, Time, with guidance from the University of Washington Alliance for Pan- demic Preparedness, polled 73 experts in late May about potential mitigation initiatives. The 73 respondents, who are thought leaders in public health, infectious disease, immunolo- gy, hospital administration, data and technology, environment and climate, health inequity, sup- ply chains, and biosecurity, rated about 50 initiatives that could mit- igate the next health crisis based on priority and feasibility. The ini- tiatives were rated on a scale of 1 to 5, with 5 being the top of the list. A third of the experts were out- side the U.S., across 16 countries. Here are average ratings for 10 of the strategies: 1. Increase investment to fur- ther future vaccine research and development Feasibility: 4.5 Priority: 4.8 2. Increase global manufactur- ing to quickly produce vaccines at scale Feasibility: 4.1 Priority: 4.8 3. Bolster the public health work- force, particularly in rural and remote regions Feasibility: 3.4 Priority: 4.6 4. Implement healthcare reforms that support universal health coverage Feasibility: 3.1 Priority: 4.5 5. Ensure strong, federally coordi- nated responses that provincial, state and local jurisdictions can rely on for guidance Feasibility: 3.6 Priority: 4.5 6. Invest in standardized, au- tomated public health records systems in countries that re- quire improvements Feasibility: 3.5 Priority: 4.4 7. Train front-line workers to screen for diseases and to prepare for emergency measures Feasibility: 3.9 Priority: 4.4 8. Provide more monetary and political support to the World Health Organization Feasibility: 3.5 Priority: 4.2 9. Amend global patent laws to encourage technology sharing Feasibility: 2.8 Priority: 4.0 10. Augment funding and re- search for artificial intelligence analytics technology Feasibility: 3.8 Priority: 3.6 n